Tevogen opened lower at $5.48, compared with its previous close of $6.00. In the last trading session, the stock traded between $5.06 and $6.87. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Tevogen is now worth
$ 1.08
Resulting in a loss of
$ 98.92 (98.92%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
$-0.58 (-9.73%)
Day High
$6.87
Day Low
$5.06
Day Open
$5.48
Prev Close
$6.00
Volume
17,449
1W Return
-5.58%
1M Return
-19.36%
3M Return
-17.81%
6M Return
-22.63%
1Y Return
-76.95%
Market Cap ($ Mn)
35
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
687.40%
EPS (TTM)
-
1 Week
-5.58%
1 Month
-19.36%
3 Months
-17.81%
6 Months
-22.63%
9 Months
-57.50%
Tevogen extends loan agreement to May 2029 with $28.6 million capacity
Tevogen extended its loan agreement with The Patel Family, LLP from May 2027 to May 2029. Borrowing capacity under the amended facility is set at up to $28.6 million. The debt facility complements an existing ATM equity program capped at $50 million. Repayment options include cash or shares, subject to applicable terms.
3 days agoTevogen targets Q4 2026 close for HRK Healthcare acquisition
Tevogen Inc. signed a non-binding LoI to acquire HRK Healthcare LLC on October 8, 2026. CEO Ryan Saadi indicated the transaction could close by the end of Q4 2026. Lead investor Dr. Manmohan Patel projects **$100 million** in combined annual revenue post-integration. The deal supports Tevogen’s expansion into healthcare services alongside biopharma and AI arms.
1mo agoTevogen regains Nasdaq compliance on $50 million market value rule
Tevogen regained compliance with Nasdaq's $50 million market value of listed securities rule. Written notice from Nasdaq received on September 29, 2026, confirming the status. Compliance with publicly held shares rule was already regained on September 9, 2026. All related Nasdaq listing compliance matters are now closed.
1mo agoTevogen Bio Holdings rebrands to Tevogen Inc. effective July 30
Tevogen Bio Holdings Inc. is rebranding to Tevogen Inc. effective July 30, 2026, to reflect its expansion into a healthcare enterprise combining biotech, AI, and services. The Nasdaq ticker TVGN remains unchanged, as do CUSIP numbers. CEO Ryan Saadi stated the move highlights the convergence of science, technology, and patient care to improve medicine affordability.
3mo agoTevogen Bio sets 2026 annual meeting for August 24
Tevogen Bio Holdings Inc. will hold its 2026 Annual Meeting of Stockholders virtually on August 24, 2026. Stockholders of record as of July 23, 2026, are entitled to vote. The company established July 23, 2026, as the deadline for stockholder proposals and director nominations under SEC Rule 14a-8 and its bylaws.
4mo agoTevogen forms healthcare services initiative to boost revenue
Tevogen Bio Holdings Inc. formed a healthcare services initiative to evolve into a broader healthcare enterprise, targeting $100 million in combined annual revenue. Led by William Keane, the initiative evaluates acquisitions of a Management Services Organization (MSO) and a Contract Research Organization (CRO) to enhance infrastructure and research capabilities. The move aligns with Tevogen's mission to improve healthcare affordability and access.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in Tevogen is now worth
$ 1.08
Resulting in a loss of
$ 98.92 (98.92%)
Note: Past profits do not guarantee future returns.
